Through review of Kinnov phase 2 trial results, and interview with Henri-Jean Aubin, Alain Puech and Emmanuel de Rivoire, Outsourcing-Pharma shares an article providing key answers as to why people affected with AUD could see their alcohol intake reduced by half in three months thanks to Kinnov therapeutics’s KT-110:

Outsourcing-Pharma has been the leading online news source for the pharma industry for more than 16 years.

For Kinnov phase 2 trial, Henri-Jean Aubin is the coordinating investigator, Alain Puech is the medical director, and Emmanuel de Rivoire is the managing director of Kinnov Therapeutics.